Association Between PCSK9 Inhibitor Use and Risk of Incident Heart Failure in Patients With Dyslipidemia

Clicks: 52
ID: 328202
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #12 of 192 articles by views in qjm : monthly journal of the association of physicians

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 192 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
AIM: To evaluate whether the use of proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9is) is associated with a reduced 1-year incidence of new-onset heart failure (HF) compared to statins among patients with dyslipidemia. METHODS: We conducted a retrospective cohort study using the TriNetX global health research network. Adults diagnosed with dyslipidemia and initiated on either PCSK9is or statins between 2015 and 2025 were included. One-to-one propensity score matching (PSM) was applied to balance baseline characteristics. The primary outcome was new-onset HF within one year. Cox proportional hazards models were used to estimate hazard ratios (HRs), with E-values calculated to assess unmeasured confounding. RESULTS: After PSM, 40,098 patients were included in each group. The incidence of new-onset HF was significantly lower in the PCSK9is group (1.8 vs. 2.7 per 100 person-years; HR 0.69, 95% CI 0.63-0.76; P < .001). Subgroup analyses confirmed consistent benefit across age, sex, and comorbidity strata. Secondary outcomes including all-cause mortality, hospitalization, and MACEs were also significantly reduced in the PCSK9is group. A negative control outcome showed no significant association. CONCLUSIONS: Among patients with dyslipidemia, PCSK9i use was associated with a significantly lower 1-year risk of new-onset HF and improved secondary outcomes compared to statin therapy. These findings support a potential preventive role of PCSK9is in HF, warranting further prospective studies to confirm these observations.
Reference Key
openalex_W7212124589 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Jheng-Yan Wu, Keng-Wei Lee, Sheng-Chi Huang, Hsuan-Yuan Chang, Yu-Min Lin
Are you one of these authors? Claim your profile
Journal qjm : monthly journal of the association of physicians
Year 2026
DOI
10.1093/qjmed/hcag235
URL
https://doi.org/10.1093/qjmed/hcag235
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.